Physician profile
Brian T Clancy
NPI 1083151898
$17,109.04
in general payments reported to CMS, 2019-2025
34 companies · $5,376 in 2025
The $5,376 reported for 2025 was more than what 99% of Physician Assistant providers received nationally (typical 2025 total: $183).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2021: $1,948 · 2022: $2,777 · 2023: $3,485 · 2024: $3,524 · 2025: $5,376.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $11K · Consulting Fee: $1,245 · Education: $192 · Travel and Lodging: $71.40.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $10,875.89 |
| Consulting Fee | $1,245.00 |
| Education | $192.24 |
| Travel and Lodging | $71.40 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Janssen Biotech, INC. | $3,227.86 | 2021-2025 | Tremfya, Stelara, Simponi Aria |
| Abbvie INC. | $2,925.57 | 2021-2025 | |
| Takeda Pharmaceuticals U.S.A., INC. | $1,746.14 | 2021-2025 | Entyvio, Eohilia, Gattex |
| Salix Pharmaceuticals, A Division of Bausch Health US, LLC | $1,650.26 | 2021-2025 | Xifaxan, Plenvu, Trulance |
| Celgene Corporation | $1,196.98 | 2021-2024 | Zeposia |
| Pfizer INC. | $779.84 | 2021-2025 | |
| Ardelyx, INC. | $732.30 | 2022-2025 | Ibsrela |
| Lilly USA, LLC | $610.86 | 2021-2025 | Omvoh |
| Ipsen Biopharmaceuticals, INC | $501.38 | 2024-2025 | Iqirvo |
| Madrigal Pharmaceuticals | $464.06 | 2024-2025 | Rezdiffra, Resmetirom |
| Qol Medical, LLC | $427.09 | 2021-2025 | Sucraid, Sucraid |
| Gilead Sciences, INC. | $321.28 | 2021-2025 | |
| Ironwood Pharmaceuticals, INC | $318.26 | 2021-2024 | Linzess |
| Genzyme Corporation | $283.04 | 2023-2025 | |
| Aimmune Therapeutics, INC. | $274.68 | 2024-2025 | Zenpep, Vowst |
Show all 34 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Intercept Pharmaceuticals, INC. | $211.57 | 2022-2024 | Ocaliva |
| Regeneron Healthcare Solutions, INC. | $204.08 | 2022-2025 | Dupixent |
| Phathom Pharmaceuticals, INC. | $176.09 | 2024-2025 | Voquezna |
| Merck Sharp & Dohme LLC | $143.36 | 2021-2024 | Dificid |
| Nestle Healthcare Nutrition INC. | $137.12 | 2021-2023 | |
| E.R. Squibb & Sons, L.L.C. | $113.90 | 2023 | |
| Fresenius Kabi USA, LLC | $106.33 | 2023-2024 | Idacio |
| Redhill Biopharma INC. | $101.76 | 2021-2023 | Movantik, Aemcolo, Talicia |
| Ferring Pharmaceuticals INC. | $97.48 | 2021-2025 | Rebyota, Clenpiq, Cimzia |
| Amgen INC. | $66.20 | 2021-2022 | |
| Organon LLC | $64.62 | 2021-2025 | Renflexis, Hadlima |
| Daiichi Sankyo INC. | $40.10 | 2021-2023 | Injectafer |
| Exact Sciences Corporation | $38.58 | 2025 | Cologuard Collection Kit, The Cologuard Plus Collection Kit |
| Vivus LLC | $36.97 | 2025 | Qsymia |
| Braintree Laboratories, INC. | $33.45 | 2022-2025 | Suflave, Sutab |
| Endo Pharmaceuticals INC. | $29.90 | 2021-2022 | |
| Shield Therapeutics INC | $21.84 | 2024 | |
| Bausch & Lomb, A Division of Bausch Health US, LLC | $16.85 | 2021 | |
| Janssen Pharmaceuticals, INC | $9.24 | 2025 |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Brian Clancy listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.